Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Vigabatrin | hsa00500 | Starch and sucrose metabolism | 1.34E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Vigabatrin | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 1.34E-02 | 2 | P06865, Q9H4F1 | HEXA, ST6GALNAC4 | More | | Vigabatrin | hsa00730 | Thiamine metabolism | 3.83E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Vigabatrin | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | Vigabatrin | hsa03008 | Ribosome biogenesis in eukaryotes | 4.94E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | | Vigabatrin | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | Vigabatrin | hsa04024 | cAMP signaling pathway | 3.37E-02 | 3 | P63092, P26678, P61586 | GNAS, PLN, RHOA | More | | Vigabatrin | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Vigabatrin | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | | Vigabatrin | hsa04064 | NF-kappa B signaling pathway | 2.15E-02 | 7 | P14778, P19174, Q04759, P06239, P09341, P19875, Q06643 | IL1R1, PLCG1, PRKCQ, LCK, CXCL1, CXCL2, LTB | More | | Vigabatrin | hsa04071 | Sphingolipid signaling pathway | 4.27E-02 | 1 | Q02156 | PRKCE | More | | Vigabatrin | hsa04072 | Phospholipase D signaling pathway | 5.37E-03 | 8 | P42338, P61586, P43657, P25024, P25025, P19174, O14986, P63092 | PIK3CB, RHOA, P2RY5, CXCR1, CXCR2, PLCG1, PIP5K1B, GNAS | More | | Vigabatrin | hsa04137 | Mitophagy - animal | 2.52E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | | Vigabatrin | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Vigabatrin | hsa04270 | Vascular smooth muscle contraction | 4.59E-02 | 1 | Q02156 | PRKCE | More | | Vigabatrin | hsa04310 | Wnt signaling pathway | 4.17E-03 | 3 | P61586, P19784, P67870 | RHOA, CSNK2A2, CSNK2B | More | | Vigabatrin | hsa04510 | Focal adhesion | 4.07E-02 | 3 | O14986, P61586, Q16363 | PIP5K1B, RHOA, LAMA4 | More | | Vigabatrin | hsa04520 | Adherens junction | 1.38E-04 | 3 | P19784, P67870, P61586 | CSNK2A2, CSNK2B, RHOA | More | | Vigabatrin | hsa04610 | Complement and coagulation cascades | 1.30E-05 | 1 | P0C0L4 | C4A | More | | Vigabatrin | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | Vigabatrin | hsa04650 | Natural killer cell mediated cytotoxicity | 4.15E-04 | 10 | P19174, P78314, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015 | PLCG1, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B | More | | Vigabatrin | hsa04658 | Th1 and Th2 cell differentiation | 8.66E-06 | 11 | Q04759, P07766, P20963, P09693, Q16539, P19174, P06239, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, LCK, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Vigabatrin | hsa04659 | Th17 cell differentiation | 3.15E-05 | 11 | Q04759, Q16539, P19174, P06239, P14784, P13765, P14778, Q9UL17, P07766, P09693, P20963 | PRKCQ, MAPK14, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, CD3E, CD3G, CD247 | More | | Vigabatrin | hsa04660 | T cell receptor signaling pathway | 3.37E-03 | 8 | Q04759, P42338, P19174, P07766, P20963, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, CD3E, CD247, CD8A, CBLB, LCK | More | | Vigabatrin | hsa04666 | Fc gamma R-mediated phagocytosis | 4.59E-02 | 1 | Q02156 | PRKCE | More | | Vigabatrin | hsa04713 | Circadian entrainment | 4.94E-02 | 2 | P62873, P63092 | GNB1, GNAS | More | | Vigabatrin | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | | Vigabatrin | hsa04724 | Glutamatergic synapse | 3.65E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | | Vigabatrin | hsa04726 | Serotonergic synapse | 2.52E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | | Vigabatrin | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.25E-03 | 6 | P14778, Q02156, P19174, P42338, P24723, Q04759 | IL1R1, PRKCE, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Vigabatrin | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Vigabatrin | hsa04925 | Aldosterone synthesis and secretion | 3.62E-02 | 1 | Q02156 | PRKCE | More | | Vigabatrin | hsa04930 | Type II diabetes mellitus | 9.93E-03 | 1 | Q02156 | PRKCE | More | | Vigabatrin | hsa04931 | Insulin resistance | 2.64E-02 | 1 | Q02156 | PRKCE | More | | Vigabatrin | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.31E-02 | 1 | Q02156 | PRKCE | More | | Vigabatrin | hsa04972 | Pancreatic secretion | 3.65E-02 | 2 | P63092, P61586 | GNAS, RHOA | More | | Vigabatrin | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Vigabatrin | hsa04974 | Protein digestion and absorption | 9.93E-03 | 1 | Q7Z2H8 | SLC36A1 | More | | Vigabatrin | hsa05032 | Morphine addiction | 2.47E-03 | 3 | P62873, P48169, P63092 | GNB1, GABRA4, GNAS | More | | Vigabatrin | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Vigabatrin | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | | Vigabatrin | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Vigabatrin | hsa05144 | Malaria | 1.44E-02 | 4 | P60033, O60603, P35443, P26718 | CD81, TLR2, THBS4, KLRK1 | More | | Vigabatrin | hsa05146 | Amoebiasis | 2.21E-04 | 8 | P09341, P19875, P14778, P27930, P42338, P11215, P05089, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, PIK3CB, ITGAM, ARG1, ACTN1 | More | | Vigabatrin | hsa05150 | Staphylococcus aureus infection | 4.36E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | | Vigabatrin | hsa05163 | Human cytomegalovirus infection | 2.09E-02 | 4 | P62873, P61586, P63092, P61769 | GNB1, RHOA, GNAS, B2M | More | | Vigabatrin | hsa05169 | Epstein-Barr virus infection | 4.41E-02 | 8 | P13765, Q13547, O00463, Q16539, P24522, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, GADD45A, TLR2, CD3G, CD247 | More | | Vigabatrin | hsa05214 | Glioma | 4.10E-02 | 2 | P09619, Q02750 | PDGFRB, MAP2K1 | More | | Vigabatrin | hsa05218 | Melanoma | 1.34E-02 | 2 | P09619, Q02750 | PDGFRB, MAP2K1 | More | | Vigabatrin | hsa05230 | Central carbon metabolism in cancer | 4.10E-02 | 2 | P09619, Q02750 | PDGFRB, MAP2K1 | More | | Vigabatrin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.00E-03 | 9 | P42338, P19174, P07766, P20963, P09693, P06239, O60603, Q04759, Q16539 | PIK3CB, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14 | More | | |